The study will include approximately 520 adult and adolescent participants (≥ 12 years of age) with SCD.~All participants will receive inclacumab 30 mg/kg administered intravenously every 12 weeks.
This study is an open-label study to evaluate the safety of long-term administration of inclacumab in participants with sickle cell disease (SCD). Participants in this study will have completed a prior study of inclacumab.